Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where’s that rocket ? Seems more like a dud to me.
Oh well, slow and steady would be good too.
Speculation at best.
Subtle difference between enrolling patients for Parkinson versus screening patients for Alzheimer?
How many of those screened have been enrolled?
You mean the preclinical research?
I don’t know about any trials for MS, do you?
Or perhaps BIIB was just not impressed and saw other drugs doing better.
Ah thats right, the good old money argument to explain the lack of partnership.
Indeed, it did go nowhere.
As for the tucked away data, BIIB partnered with someone else for MS. Says enough for me,
Quite the opposite, we have been attacked quite successfully in the last years. Look were we are now. Sub $2 with a high of $14 back in 2015.
I’ve heard he same in 2015, 16, 17, 18
Why would 2019 be any different for Anavex?
Is that eternal BIIB-testing of 2-73 still ongoing or can we finally conclude it is going nowhere?
Seems when everything goes, AVXL still goes up. Disheartening.
99% failure in Alzheimer trials, but yeah Anavex will be different, each company thinks and says that.
I wish Missling was as meticuluos with this trial initiations.
AD is off by a year.
Volume is still average. It goes with the market.
Wish we had more strength...
The cabal has been in control since 2015
Given the 99.% failure rate, the odds are a little hard to beat.
Even institutional holders are giving up.
a 100-bagger from $8 or $1.5 makes a big difference.
Good, so we agree, institutional ownership in Anavex is down from 25% to 17%.
I'll take that as a sign of market confidence.
The rest is speculation.
Trouble is that if one bought stock in previous years, then the flying feels more like share price crashing.
Nasdaq uplisting happened at $8, look were we are now.
Soon to be kicked off Nasdaq??
Institutional holders are bailing too. Down from 25% to 17,6%
"being smart and loading up" is not working out as the share price just goes lower and lower and lower.
I've heard that song too often, at $ 4, at $3, at $2, etc...
Can I have free shares too please?
Good for you! I prefer to make money.
Oh please enlighten me what the Crappy Doctor is doing to bolster our shareprice?
Starting trials a year later then promised is not really impressing the market.
It seems the Good Doctor doesn’t really care about his bleeding shareholders. I wouldnt either if i was given tons of freebie shares.
Markets go jibbery on China-US trade. These kind of these always get abused to walk down small caps.
Imagine if he needs to raise cash at this pathetic shareprice. He seems not very Good at creating let alone maintaining shareholder value...
No shit Sherlock...
From IR:
Hi,
Thank you for reaching out. In regards to when we plan on doing the Q3 call, please keep a lookout for a press release when we announce it to the public.
Thank you.
Keep in mind that $4 was a fair price at that time. Shareprice only took off when the merger was annonced.
Disregard the disinformation.
Guess what price target got hit? 6.06
Scary!
Yes: ages.
How would I know? Better ask IR.
Great market action, down again. Seems never to able to hold a gain.
So 15 patients in the 7 week Pharmacokinetic a and dose finding.
How many in the 3 month placebo-controlled safety and efficacy trial?
Some big boys MM’s shakIng the tree for weak hands.
New DOD grant, this time for TPIV110 and Herceptin!!
Mayo Clinic Receives $11 Million to Study TPIV110 in Combination with Trastuzumab (Herceptin®)
Jacksonville FL, October 10, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, congratulates Mayo Clinic for being awarded a grant of $11 million from the U.S. Department of Defense (DoD). This grant will cover the costs of a large Phase 2 study of TapImmune’s HER2/neu-targeted breast cancer vaccine, TPIV110, in combination with another immunotherapeutic, trastuzumab (Herceptin®), for treating women with HER2/neu-positive breast cancer.
Award recipients are Keith L. Knutson, Ph.D., Professor of Immunology in the Department of Immunology and Saranya Chumsri, M.D. in the Division of Hematology and Oncology at Mayo Clinic in Jacksonville, Florida.
TapImmune will work closely with Mayo Clinic on this clinical trial by providing clinical and manufacturing expertise as well as providing GMP vaccine formulations.
Peter L. Hoang, President and CEO of TapImmune, stated, “I am delighted that the U.S. Department of Defense has again chosen to support our technology and therapeutic platform with another funding commitment. This grant speaks to the strength and quality of the DoD’s relationship with Dr. Knutson and the Mayo Clinic. This new 380-patient trial will be the largest to date for TapImmune, and I note that the Department of Defense has now awarded almost $30 million in grants to study our novel vaccine candidates in Phase 2 clinical studies. We are grateful to the DoD for their continued efforts to support the development of new and potentially life-saving treatment modalities for women suffering from breast cancer. Like Dr. Knutson’s team at the Mayo, we believe that the underlying science indicates that TPIV110 has strong potential to synergize with Herceptin® and generate enhanced levels of protective immunity in patients with aggressive HER2-positive breast cancer.”
This is the second DoD grant to be awarded to the Mayo Clinic to study TPIV110, which is also the subject of a planned, DoD-funded Phase 2 study in women with ductal carcinoma in situ (DCIS). This newest grant also marks the third awarded to fully fund clinical trials of TapImmune’s novel peptide vaccine candidates.
Previously, TapImmune announced that the Mayo Clinic plans to conduct a Phase 2 clinical study of TPIV110 that will enroll women diagnosed with DCIS, an early form of breast cancer. If successful, the vaccine may be positioned to complement standard surgery and chemotherapy in this setting and potentially could become part of a routine immunization schedule for preventing breast cancer in healthy women.
TapImmune is also currently enrolling women into a 280-patient Phase 2 randomized, multi-center, double-blinded, placebo-controlled clinical trial of its novel therapeutic vaccine candidate TPIV200, which is funded by a $13.3 million DoD grant. This study is evaluating TPIV200 in the prevention of cancer recurrence in women with triple-negative breast cancer (TNBC) who have completed first-line surgery and radiotherapy/chemotherapy. This program is eligible for FDA Fast Track designation.
Mayo Clinic and Dr. Knutson have a financial interest in the technology referenced in this news release.
Waiting for the PR :)))
Surely 2-73 causes brain swelling to longtime shareholders